Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original) A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg/ml, 1,2-propylene glycol, an aqueous buffer, a non-ionic surfactant, and a preservative, said pharmaceutical formulation having a tonicity of from about 100 mosm/kg to about 500 mosm/kg and having a pH from about 6.1 and about 6.3.

Claim 2. (original) The pharmaceutical composition according to claim 1, additionally comprising a tonicity-adjusting agent such that the tonicity of the pharmaceutical composition is from about 100 mosm/kg to about 500 mosm/kg.

Claim 3. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the concentration of human growth hormone is from about 6 mg/ml to 14 mg/ml.

Claim 4. (canceled)

Claim 5. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the concentration of 1,2-proplene glycol is from about 0.5 mg/ml to about 20 mg/ml.

Claim 6. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the concentration of 1,2-proplene glycol is from about 5 mg/ml to about 15 mg/ml.

Claim 7. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the aqueous buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.

Claim 8. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the aqueous buffer is a phosphate buffer.

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (currently amended) The pharmaceutical formulation according to claim 1~~ or claim 2~~, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer, a Pluronic ® polyol and a polysorbate.

Claim 13. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the non-ionic surfactant is a poloxamer.

Claim 14. (canceled)

Claim 15. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the preservative is selected from the group consisting of benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, 2-phenoxyethanol, phenyl mercuric nitrate and thimerosal.

Claim 19. (canceled)

Claim 20. (canceled)

Claim 21. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the optional tonicity-adjusting agent is selected from the group consisting of a sugar, a sugar alcohol, a further polyol, a neutral salt, and an amino acid.

Claim 22. (currently amended) The pharmaceutical formulation according to ~~claim 19~~ claim 21, wherein the tonicity-adjusting agent is mannitol.

Claim 23. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, said pharmaceutical composition being substantially isotonic.

Claim 24. (original) The pharmaceutical formulation according to claim 1, said pharmaceutical composition having a pH of about 6.2.

Claim 25. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, essentially consisting of 6.67 mg/ml human growth hormone,
from about 6 mg/ml to 15 mg/ml propylene glycol,
10 mM sodium phosphate buffer,
2 mg/ml poloxamer 188,
where necessary mannitol at a concentration sufficient such that the formulation is substantially isotonic,
and having a pH of 6.2.

Claim 26. (currently amended) The pharmaceutical composition according to claim 1 ~~or claim 2~~, essentially consisting of 6.67 mg/ml human growth hormone,
6 mg/ml propylene glycol,
10 mM sodium phosphate buffer,
22.5 mg/ml mannitol,
2 mg/ml poloxamer 188,
and having a pH of 6.2.

Claim 27. (currently amended) The pharmaceutical composition according to claim 1 ~~or claim 2~~, essentially consisting of 6.67 mg/ml human growth hormone,
9 mg/ml propylene glycol,
10 mM sodium phosphate buffer,
8.1 mg/ml mannitol,
2 mg/ml poloxamer 188,
and having a pH of 6.2.

Claim 28. (original) The pharmaceutical composition according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,
12.4 mg/ml propylene glycol,
10 mM sodium phosphate buffer,
2 mg/ml poloxamer 188,
and having a pH of 6.2.

Claim 29. (currently amended) A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1 ~~or claim 2~~.